NCT04271384View on ClinicalTrials.gov

Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2023

Conditions
Non-small Cell Lung Cancer Stage I
Interventions
COMBINATION_PRODUCT

nivolumab

Combined neoadjuvant therapy consisting of nivolumab + SABR

Trial Locations (1)

05651-901

Hospital Israelita Albert Einstein, São Paulo

All Listed Sponsors
lead

Hospital Israelita Albert Einstein

OTHER

NCT04271384 - Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter